- Home
- SLQT vs CYBN Comparison
SLQT vs CYBN Comparison
Compare SLQT & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | CYBN |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.6M | 298.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLQT | CYBN |
|---|---|---|
| Price | $1.51 | $6.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.88 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 864.0K | 626.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,563,142,000.00 | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $1.33 | $4.81 |
| 52 Week High | $6.86 | $10.73 |
Technical Indicators
Market Signals| Indicator | SLQT | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 60.06 |
| Support Level | $1.38 | $5.70 |
| Resistance Level | $1.50 | $6.20 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 75.00 | 85.82 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.